HRP20192195T1 - Derivati 7-(morfolin-4-il)pirazol[1,5-a]pirimidina koji su korisni za liječenje imunoloških ili upalnih oboljenja ili karcinoma - Google Patents

Derivati 7-(morfolin-4-il)pirazol[1,5-a]pirimidina koji su korisni za liječenje imunoloških ili upalnih oboljenja ili karcinoma Download PDF

Info

Publication number
HRP20192195T1
HRP20192195T1 HRP20192195TT HRP20192195T HRP20192195T1 HR P20192195 T1 HRP20192195 T1 HR P20192195T1 HR P20192195T T HRP20192195T T HR P20192195TT HR P20192195 T HRP20192195 T HR P20192195T HR P20192195 T1 HRP20192195 T1 HR P20192195T1
Authority
HR
Croatia
Prior art keywords
methyl
morpholin
pyrazolo
pyrimidine
indol
Prior art date
Application number
HRP20192195TT
Other languages
English (en)
Croatian (hr)
Inventor
Barbara DYMEK
Marcin ZAGOZDA
Maciej Wieczorek
Krzysztof DUBIEL
Aleksandra Stanczak
Daria ZDZALIK
Pawel GUNERKA
Mariola SEKULAR
Maciej DZIACHAN
Original Assignee
Celon Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celon Pharma S.A. filed Critical Celon Pharma S.A.
Publication of HRP20192195T1 publication Critical patent/HRP20192195T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HRP20192195TT 2015-04-02 2016-03-30 Derivati 7-(morfolin-4-il)pirazol[1,5-a]pirimidina koji su korisni za liječenje imunoloških ili upalnih oboljenja ili karcinoma HRP20192195T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PL411864A PL236355B1 (pl) 2015-04-02 2015-04-02 Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
PCT/IB2016/051792 WO2016157091A1 (en) 2015-04-02 2016-03-30 7-(morpholin-4-yl)pyrazole[1,5-a]pyrimidine derivatives which are useful for the treatment of immune or inflammatory diseases or cancer
EP16714019.3A EP3277687B1 (en) 2015-04-02 2016-03-30 7-(morpholin-4-yl)pyrazole[1,5-a]pyrimidine derivatives which are useful for the treatment of immune or inflammatory diseases or cancer

Publications (1)

Publication Number Publication Date
HRP20192195T1 true HRP20192195T1 (hr) 2020-03-06

Family

ID=55650626

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20192195TT HRP20192195T1 (hr) 2015-04-02 2016-03-30 Derivati 7-(morfolin-4-il)pirazol[1,5-a]pirimidina koji su korisni za liječenje imunoloških ili upalnih oboljenja ili karcinoma

Country Status (18)

Country Link
US (1) US10138247B2 (enExample)
EP (1) EP3277687B1 (enExample)
JP (1) JP6665201B2 (enExample)
KR (1) KR102559190B1 (enExample)
CN (1) CN107743489B (enExample)
AU (1) AU2016241568B2 (enExample)
BR (1) BR112017020131B1 (enExample)
CA (1) CA2978828A1 (enExample)
DK (1) DK3277687T3 (enExample)
EA (1) EA032826B1 (enExample)
ES (1) ES2765642T3 (enExample)
HR (1) HRP20192195T1 (enExample)
HU (1) HUE047822T2 (enExample)
MX (1) MX2017011423A (enExample)
PL (2) PL236355B1 (enExample)
PT (1) PT3277687T (enExample)
SI (1) SI3277687T1 (enExample)
WO (1) WO2016157091A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12486274B2 (en) 2020-01-13 2025-12-02 Verge Analytics, Inc. Substituted pyrazolo-pyrimidines and uses thereof
WO2022064458A1 (en) * 2020-09-28 2022-03-31 1ST Biotherapeutics, Inc. Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods of using same
EP4229063A4 (en) * 2020-10-19 2024-12-25 TME Therapeutics LLC NOVEL PIKFYVE INHIBITORS AND METHODS OF USE THEREOF
CN114957261B (zh) * 2022-05-17 2023-06-23 重庆文理学院 一种具有抗头颈癌作用的化合物及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2168237T3 (es) * 1996-02-07 2007-04-01 Neurocrine Biosciences, Inc. Pirazolopirimidinas como antagonistas de receptores de crf.
CN1918172B (zh) 2003-12-23 2011-09-14 活跃生物工艺学公司 利福霉素类似物及其用途
ATE512966T1 (de) * 2005-02-11 2011-07-15 Hoffmann La Roche Pyrazolo-pyrimidin-derivate als mglur2- antagonisten
KR101088239B1 (ko) * 2006-09-20 2011-11-30 일라이 릴리 앤드 캄파니 Crf1 수용체 길항제로서의 티아졸 피라졸로피리미딘
JP5638955B2 (ja) * 2007-10-26 2014-12-10 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Pi3キナーゼ阻害剤として有用なプリン誘導体
EA201001359A1 (ru) 2008-02-26 2011-04-29 Новартис Аг Гетероциклические соединения в качестве ингибиторов cxcr2
ES2533788T3 (es) * 2008-05-30 2015-04-14 Genentech, Inc. Compuestos inhibidores de PI3K de tipo purina y métodos de uso
WO2010037765A2 (en) * 2008-10-03 2010-04-08 Merck Serono S.A. 4-morpholino-pyrido[3,2-d]pyrimidines
WO2010074284A1 (ja) * 2008-12-26 2010-07-01 味の素株式会社 ピラゾロピリミジン化合物
NZ596185A (en) * 2009-04-16 2013-01-25 Ct Nac Investigaciones Oncologicas Cnio Imidazopyrazines for use as kinase inhibitors
SG182247A1 (en) 2009-05-27 2012-08-30 Hoffmann La Roche Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
MX2011012520A (es) * 2009-05-27 2011-12-12 Hoffmann La Roche Compuestos inhibidores de pi3k de pirimidina biciclicos selectivos para p110 delta y metodos de uso de los mismos.
GB0912745D0 (en) 2009-07-22 2009-08-26 Wolfson Microelectronics Plc Improvements relating to DC-DC converters
MX2012009059A (es) 2010-02-22 2012-09-07 Hoffmann La Roche Compuestos inhibidores de fosfoinositida 3-cinasa delta (pi3k) pirido [3,2-d]pirimidina y metodos de uso.
CA2789475C (en) 2010-03-04 2018-05-29 Merck Sharp & Dohme Corp. Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders
WO2013028263A1 (en) * 2011-08-24 2013-02-28 Glaxosmithkline Llc Pyrazolopyrimidine derivatives as pi3 kinase inhibitors

Also Published As

Publication number Publication date
ES2765642T3 (es) 2020-06-10
BR112017020131B1 (pt) 2023-02-28
PL411864A1 (pl) 2016-10-10
CN107743489A (zh) 2018-02-27
HUE047822T2 (hu) 2020-05-28
KR102559190B1 (ko) 2023-07-25
AU2016241568B2 (en) 2019-09-26
SI3277687T1 (sl) 2020-02-28
US20180111939A1 (en) 2018-04-26
PL3277687T3 (pl) 2020-09-21
US10138247B2 (en) 2018-11-27
EA032826B1 (ru) 2019-07-31
JP6665201B2 (ja) 2020-03-13
BR112017020131A2 (pt) 2018-05-29
PL236355B1 (pl) 2021-01-11
EP3277687A1 (en) 2018-02-07
DK3277687T3 (da) 2019-12-16
PT3277687T (pt) 2020-01-10
CN107743489B (zh) 2021-05-04
KR20170132275A (ko) 2017-12-01
AU2016241568A1 (en) 2017-10-19
JP2018510192A (ja) 2018-04-12
CA2978828A1 (en) 2016-10-06
MX2017011423A (es) 2018-05-17
EP3277687B1 (en) 2019-10-30
EA201792087A1 (ru) 2018-03-30
WO2016157091A1 (en) 2016-10-06

Similar Documents

Publication Publication Date Title
RU2018138471A (ru) Гетероциклические соединения в качестве ингибиторов киназы RET
TWI805629B (zh) 用於治療發炎性病症之新穎化合物及其醫藥組合物
RU2019115115A (ru) Производные пиперидина в качестве ингибиторов убиквитин-специфической протеазы 7
HRP20200624T1 (hr) Derivati 2-(2,4,5-supstituiranog-anilino)pirimidina kao modulatori egfr korisni za liječenje raka
NZ766835A (en) Pharmaceutical compounds
RU2014151004A (ru) Пирролопиримидоновые и пирролопиридоновые ингибиторы танкиразы
JP2023549055A5 (enExample)
UY37925A (es) Formas cristalinas
RU2015154676A (ru) Соединения для лечения спинальной мышечной атрофии
IL257587A (en) Compounds for the treatment of lateral amyotrophic sclerosis
RU2016151315A (ru) Некоторые ингибиторы протеинкиназы
HRP20192159T1 (hr) Spojevi za liječenje mišićne atrofije kralježnice
HRP20211642T1 (hr) Derivati benzizotiazola, izotiazolo[3,4-b]piridina, kinazolina, ftalazina, pirido[2,3-d]piridazina i pirido[2,3-d]pirimidina kao inhibitori kras g12c za liječenje raka pluća, gušterače ili kolorektalnog karcinoma
HRP20191268T1 (hr) Derivati tieno[2,3-c]pirol-4-ona kao inhibitori erk
JP2011511034A5 (enExample)
SI3083625T1 (en) Pyrimidopyrimidinones, useful as Wee-1 kinase inhibitors
PH12016501164A1 (en) Heteroaryl substituted nicotinamide compounds
EP4237086A1 (en) Heterocyclic spiro compounds and methods of use
HRP20151398T1 (hr) Tricikliäśni derivati amina kao inhibitori protein tirozin kinaze
JP2019515903A5 (enExample)
RU2015148189A (ru) ПРОИЗВОДНЫЕ 2-АМИДОПИРИДО[4, 3-d]ПИРИМИДИН-5-ОНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ WEE-1
HRP20170712T1 (hr) Novi spojevi selektivnih antagonista nk-3 receptora, farmaceutski pripravak i postupci za uporabu kod poremećaja uzrokovanih nk-3 receptorima
RU2012148133A (ru) Комбинация, включающая ингибитор циклинзависимой киназы 4 или циклинзависимой киназы 6 (cdk4/6) и ингибитор mtor, для лечения рака
JP2016537384A5 (enExample)
NZ628186A (en) Compounds for treating spinal muscular atrophy